![](https://investorshub.advfn.com/uicon/350406.png?cb=1547729749)
Saturday, June 04, 2016 8:09:15 AM
Teva Painkiller Resists Snorting, Injection Abuse, FDA Staff Say
http://www.bloomberg.com/news/articles/2016-06-03/teva-painkiller-resists-snorting-injection-abuse-fda-staff-say
FDA staff says in report Vantrela may not prevent oral abuse
Teva Pharmaceutical Industries Ltd.’s hydrocodone painkiller works to deter people who might try to crush the drug and snort or inject it to get high, U.S. regulators said.
The extended-release tablets, called Vantrela ER, showed better resistance to abuse by inhalation and injection than other hydrocodone capsules, Food and Drug Administration staff said in a report released Friday. Yet the data from testing isn’t sufficient to establish that the pain pill would be superior at preventing oral abuse, according to the report.
Agency advisers will meet Tuesday to recommend whether the label on Teva’s painkiller should make abuse-deterrent claims. FDA reviewers typically offer their analysis of clinical trials and any lingering concerns before such meetings.
Pharmaceutical companies have worked to develop abuse-deterrent painkillers over the past several years, particularly as opioid addiction has become epidemic in the U.S. The FDA has approved six pain medications with labels describing the properties that make them difficult for recreational drug users to abuse. Those can include gelling agents, the addition of a drug that interferes with the euphoria linked to abuse, or substances that would make abuse unpleasant, such as a nasal irritant.
Pfizer Drug
Pfizer Inc.’s oxycodone, which the company also wants to label as abuse-deterrent, will face the advisory panel on Wednesday. The Pfizer capsules combine oxycodone with naltrexone, which is used to reverse the effects of opioids.
Teva tested its hydrocodone against other pills, using crushing and grinding mechanisms and by dissolving the pills in solvents such as water or alcohol. While Vantrela ER’s abuse-deterrence properties work better against snorting or injecting, they are only comparable to other extended-release hydrocodone products when abusers use a solvent to extract the opioid from the other ingredients in the pill, FDA staff said in the report.
FDA staff also said that Vantrela ER is superior at deterring abuse compared to immediate-release combination hydrocodone and ibuprofen.
Other Opioids
Purdue Pharma also makes an abuse-deterrent hydrocodone called Hysingla, cleared for sale in 2014. Purdue reformulated its OxyContin in 2010 and the FDA determined in 2013 has an increased ability to resist crushing, breaking and dissolution. The agency rejected a similar request from Endo International Plc the same year to label its Opana oxymorphone pain pill as abuse-deterrent because the agency said the crush-resistant features could be manipulated by cutting or chewing.
Zogenix Inc.’s Zohydro was the first approved pure hydrocodone painkiller. Zogenix touted it as an alternative to drugs including Vicodin that mix hydrocodone with less-potent medicines such as acetaminophen. The FDA was attacked by critics for giving a green light to a powerful pain pill that didn’t include abuse-deterrent properties, but the agency said its benefits outweighed its risks. Acetaminophen can damage the liver.
About 20,000 Americans died from overdosing on prescription opioid painkillers in 2014, more than triple the number in 2001, according to the National Institutes of Health. Deaths from heroin, which also is an opioid, rose to 12,000 from 2,000 in the same period.
Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM